best peptides FAQ

GHK-Cu is the most relevant peptide for proactive tissue maintenance because it enhances collagen organization and reduces oxidative stress. Both of which degrade with age and repetitive loading. A study in Oxidative Medicine and Cellular Longevity showed that GHK-Cu administration increased superoxide dismutase (SOD) activity, which neutralizes free radicals generated during intense exercise. For surfers over 35, collagen synthesis slows and oxidative damage accumulates faster. GHK-Cu addresses both. It's not a recovery tool for acute injuries; it's a tissue health maintenance compound.

No pharmacokinetic interaction exists, but monitor for additive effects on fluid balance. Acetazolamide induces metabolic acidosis to stimulate ventilation, increasing urination significantly. MK-677 causes mild fluid retention through aldosterone modulation. The combination can produce unpredictable hydration status. Some users experience enhanced diuresis, others retain fluid despite Diamox. Practical protocol: weigh daily and track urine output. If weight increases more than 2kg during the first 48 hours at altitude despite Diamox, reduce MK-677 to 12.5mg nightly or discontinue temporarily.

This suggests dependency on exogenous signaling rather than restored endogenous rhythm. Typically caused by using peptides too long after arrival. Thymalin and Epitalon should be discontinued once you've achieved 2–3 consecutive nights of consolidated sleep in the new timezone (usually 5–7 days post-arrival). Continuing beyond this window can suppress your pineal gland's intrinsic function. Taper Selank over 2–3 days rather than stopping abruptly to avoid HPA axis rebound. If insomnia persists beyond peptide cessation, the issue is likely unresolved circadian misalignment, not peptide withdrawal.

Thymalin and KPV are the compounds with the strongest theoretical relevance. Autoimmune inner ear disease (AIED) involves immune-mediated damage to cochlear and vestibular structures. The immune system attacks inner ear antigens, causing progressive hearing loss, tinnitus, and vestibular dysfunction. Thymalin modulates T-cell activity and reduces autoimmune inflammation systemically, while KPV blocks NF-κB-driven inflammatory cascades at the cellular level. Both address the underlying immune dysregulation rather than suppressing symptoms. Research protocols investigating AIED typically involve consistent dosing over 8–12 weeks to measure changes in vestibular function tests (caloric testing, vestibular evoked myogenic potentials) and audiometric thresholds. Acute symptom relief is not the endpoint. Disease modification is.

NSAIDs blunt the prostaglandin-mediated inflammatory signals that peptides are trying to resolve productively. A 2010 study in Clinical Orthopaedics and Related Research found ibuprofen reduced fracture healing rates measurably. If pain control is necessary, use acetaminophen (paracetamol) instead. It inhibits central COX pathways without blocking peripheral prostaglandin synthesis required for tissue repair. Alternatively, reduce NSAID use to the first 48–72 hours only, then discontinue while continuing peptide protocols.

Yes, but not the peptides themselves. The timing and dose. Growth hormone secretion declines approximately 14% per decade after age 30, which compounds recovery delays in older hikers. Adding CJC-1295/Ipamorelin (100mcg each, nightly) three days before a major hike and continuing for seven days post-return offsets that hormonal deficit. BPC-157 and TB-500 dosing remains unchanged. Collagen synthesis pathways don't degrade with age the way GH secretion does.

Layer protocols sequentially. Start with BPC-157 for the tendon component (250 mcg twice daily subcutaneously near the injury), then add Cerebrolysin after two weeks for nerve repair (5 mL intramuscularly three times weekly). Introducing both simultaneously makes it impossible to identify which compound is driving improvement or causing side effects. Stagger by 10–14 days. This also prevents peptide interaction effects that haven't been studied in combination trials.

GHK-Cu is the specific peptide to prioritize when meibography (infrared imaging of eyelid glands) shows greater than 50% gland dropout. Standard warm compresses and lid hygiene can't reverse fibrosis. They maintain remaining gland function but don't restore lost tissue. GHK-Cu's matrix remodeling action demonstrated partial gland recovery in rosacea-associated MGD patients tracked over six months via serial meibography at three-month intervals. The effect isn't regeneration from zero. If a gland has completely atrophied, no current therapy rebuilds it. But early fibrotic changes (glands present but dilated/tortuous on imaging) showed 20–30% improvement in gland morphology scores, correlating with improved lipid layer thickness measured by interferometry.

Notify your orthopedic surgeon and request radiographic monitoring at weeks 4, 8, and 12. Peptides don't replace surgical fixation, casting, or weight-bearing restrictions. They augment the biological healing process within those constraints. The concern isn't peptide interference with medical treatment; it's ensuring your provider tracks healing progression accurately. Accelerated callus formation sometimes appears as increased radiopacity on X-rays, which inexperienced readers may misinterpret as abnormal calcification. Document your peptide protocol in your medical record so imaging findings are contextualized appropriately.

Combine Ipamorelin (200–300 mcg post-training and before bed) with CJC-1295 (1–2 mg weekly) to create both acute GH pulses and sustained baseline elevation. The Ipamorelin doses timed around training windows maximize recovery hormone availability when microtrauma repair is most active, while CJC-1295's extended half-life maintains systemic support between sessions.

No. Use peptides reactively, not prophylactically. Start BPC-157 250mcg daily immediately after a demanding hike (elevation gain >2,000 feet or duration >5 hours) and continue for 7–10 days. TB-500 can be added at 2mg twice weekly if you're dealing with lingering soreness or a previous injury flare-up. There's no evidence supporting continuous peptide use for recreational weekend hikers. The protocols work because they target acute recovery windows, not baseline maintenance.

Continue vestibular rehabilitation therapy alongside peptide use. Peptides enhance neuroplasticity but don't replace the physical retraining required for compensation. Vertigo resolution timelines vary: acute vestibular neuritis may show improvement in 4–8 weeks, while Meniere's disease often requires 3–6 months of combined intervention. If episodes persist beyond expected compensation windows, reevaluate the diagnosis. Some vertigo presentations (BPPV, superior canal dehiscence) require physical maneuvers or surgical correction that peptides cannot address.

Peptide therapy in periodontology is evidence-based but not yet standard-of-care. The published research exists in peer-reviewed journals (Journal of Clinical Periodontology, Journal of Periodontal Research, International Journal of Molecular Sciences), but adoption into clinical practice lags because peptides aren't FDA-approved as drugs for periodontal disease. They're used off-label or as research compounds. If your periodontist is unfamiliar, bring published studies. Specifically the 2022 RCT on thymosin beta-4 or the 2023 BPC-157 case series. Most clinicians respect data. Peptide use as an adjunct doesn't replace established surgical or non-surgical therapy. It complements it.

Peptides remain effective in the remodeling phase of healing, but the mechanism shifts. BPC-157 still promotes collagen deposition and vascular health in scar tissue, which can improve tissue quality even months later. TB-500 supports fibroblast activity that continues remodeling connective tissue for up to a year post-injury. If cognitive symptoms persist (brain fog, memory issues, mood changes), dihexa and P21 support long-term neuroplasticity rather than acute neuroprotection. The window for intervention doesn't close at 72 hours.

No, but the benefit profile changes. BPC-157 and GHK-Cu still accelerate healing during the remodeling phase (weeks 3–12 post-injury), particularly for improving collagen organization and reducing fibrotic scar tissue. TB-500's angiogenic benefit is reduced because peak capillary formation occurs in days 4–14. Starting at week two, prioritize BPC-157 for ligament injuries and GHK-Cu for reducing chronic inflammation. TB-500 becomes optional unless significant ongoing contusion is present.

Yes. Peptides and corticosteroids work through different mechanisms and can be sequenced safely. Wait 2–3 weeks after a cortisone injection before starting BPC-157 or TB-500 to allow the corticosteroid's anti-inflammatory effect to stabilise. Cortisone reduces swelling temporarily by suppressing immune response, but it doesn't address the underlying tendon inflammation or nerve compression. Peptides fill that gap by promoting tissue repair and reducing chronic inflammation through growth factor modulation rather than immune suppression.

Rotate injection sites and ensure proper reconstitution technique. Peptides mixed with bacteriostatic water (not sterile water) reduce irritation risk significantly. Inject at least 2 inches away from the previous site to prevent localised inflammation. If irritation persists, consider intramuscular administration instead of subcutaneous. BPC-157's systemic effects mean it doesn't require site-specific injection to benefit the carpal tunnel.

Potentially, if they target different mechanisms and are timed correctly. Combining pre-drinking NAD+ precursors (to maintain ALDH2 activity) with post-drinking glutathione (to neutralize ROS during peak oxidative stress) and delayed thymosin derivatives (to modulate inflammation) addresses three separate damage pathways sequentially. However, no published trials have tested multi-peptide hangover protocols. The evidence base is limited to single-compound interventions. Stacking peptides without understanding pharmacokinetics risks overlap, redundancy, or mistimed administration.

You've likely reached the structural limit of your existing collagen matrix. Static stretching alone doesn't trigger sufficient collagen turnover to remodel connective tissue. It maintains existing range but rarely increases it past a certain threshold. Add 15 grams of collagen peptides daily for 12 weeks while maintaining your current stretching protocol. Research shows this combination increases tendon compliance by 8–12% even in athletes who have plateaued for years. The peptides provide the substrate your fibroblasts need to synthesise new, more elastic collagen fibres.

No. Peptide efficacy isn't limited to the acute inflammatory phase. Start immediately. Tissue remodeling continues for 6–12 weeks post-injury, and peptides influence fibroblast activity, collagen alignment, and scar tissue formation throughout that window. A 2020 study in Wound Repair and Regeneration found that BPC-157 administered 14 days post-injury still reduced scar width by 35% compared to controls, though starting within 72 hours produced 50% reduction. The mechanism remains active as long as remodeling continues.